Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated with ianalumab also experienced a significantly higher rate of sustained improvements in platelet count, the key secondary endpoint of the study1 Ianalumab, administered as four once-monthly doses in the ITP setting, could offer long-term disease control through a short course of treatment and potentially allo ...